ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT)
Clinical trials for ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) explained in plain language.
Never miss a new study
Get alerted when new ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT) trials appear
Sign up with your email to follow new studies for ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug gilteritinib may beat standard therapy in preventing AML relapse after transplant
Disease control Recruiting nowThis Phase 3 trial tests whether the drug gilteritinib is better than sorafenib at keeping leukemia from coming back in patients with a specific gene mutation (FLT3-ITD) after a stem cell transplant. About 594 adults and teens will take one of the two pills daily for up to 2 year…
Matched conditions: ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT)
Phase: PHASE3 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 11:04 UTC
-
New pill aims to keep leukemia away after transplant
Disease control Recruiting nowThis phase II trial tests whether the drug chidamide can help prevent acute myeloid leukemia (AML) from coming back after a stem cell transplant. About 134 adults with high-risk AML who are in remission after transplant will either take chidamide pills or receive standard observa…
Matched conditions: ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION (HCT)
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC